ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   
 Top Breaking News
 Tuesday, April 28, 2015

ImmunoGen (IMGN) Has Good News, Bad News as Sanofi (SAN.PA) SAAR3419 Deal Falls Apart and Ovarian Cancer Treatment Moves Forward

Advancing Biogen (BIIB)’s Alzheimer’s Treatment Could Cost $2.5 Billion Before Knowing if the Drug Works

EXCLUSIVE: Navidea (NAVB) CEO Tells BioSpace (DHX) New Cancer Treatment Will See More Trial Data in 2015

Prior to FDA Vote, Advisory Committee Cites Study Bias Concerns Over Amgen (AMGN) Cancer Vaccine

In Fight Against Alzheimer's, $100 Million Genentech (RHHBY) Trial in Colombia May Be Ground Zero

Celladon (CLDN) Will Lay Off Workers, Loses 80% of Value As Heart Failure Drug Flunks Phase IIb Trial

Aerie (AERI) Freefalls Aftermarket as Rhopressa Fails Phase III Study

EXCLUSIVE: Jounce CEO Says Funding Aims for Trials Next Year, Will Hire 10

More News



 Yesterday's Most Popular News 
Prior to FDA Vote, Advisory Committee Cites Study Bias Concerns Over Amgen (AMGN) Cancer Vaccine

In Fight Against Alzheimer's, $100 Million Genentech (RHHBY) Trial in Colombia May Be Ground Zero

Scientists Skeptical About Secret Blood Test That Has Made Elizabeth Holmes A Billionaire

Celladon (CLDN) Will Lay Off Workers, Loses 80% of Value As Heart Failure Drug Flunks Phase IIb Trial

Aerie (AERI) Freefalls Aftermarket as Rhopressa Fails Phase III Study

EXCLUSIVE: Jounce CEO Says Funding Aims for Trials Next Year, Will Hire 10

Independence Equals Success For Women In The Dating Game, University of Queensland Study

We Think Better On Our Feet, Literally, Texas A&M University Study

Merrimack (MACK) And Baxter BioScience Corporation (BAX) Announce Completion Of New Drug Application Submission To U.S. FDA For MM-398 As A Treatment For Post-Gemcitabine Metastatic Pancreatic Cancer

Merck & Co. (MRK) Poised To Enter Oral HCV Market Dominated by Gilead (GILD) and AbbVie (ABBV)


 
-

 Featured Stories
 

  Today's Top Jobs

 Featured Employer
About Genzyme Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis. Learn more at www.jobsatgenzyme.com. Follow our jobs on Twitter www.twitter.com/genzymejobs. Follow us on LinkedIn http://www.linkedin.com/company/genzyme. About Sanofi Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Show me jobs for this employer

 Careers
 
More Career Tips